Lung cancer originates in lung tissue and often shows no early symptoms, yet precision treatment can lead to cure or long-term control.
With over 2.2 million new cases annually worldwide and nearly 70% diagnosed at advanced stages, early intervention and treatment are crucial to securing a curative window.
China reports approximately 800,000 new cases yearly—nearly one-third of the global burden—endowing our teams with a depth of experience that ensures precision in delivering individualized care. As our guiding clinical philosophy states:"The more cases we see, the more precisely we treat."
Lung cancer is often called a "silent killer" because early symptoms are easily mistaken for a common cold or aging. Do not wait until it hurts. If you experience any of the following for more than two weeks, seek expert evaluation immediately:
Symptom | What to Watch For |
Persistent Cough | A cough that does not go away or worsens, especially if you are a smoker or former smoker. |
Hemoptysis | Rust-colored sputum or blood-streaked phlegm, even in small amounts. |
Chest Pain | Sharp or dull pain that worsens with deep breathing, coughing, or laughing. |
Shortness of Breath | Wheezing or breathlessness during normal activities that did not trouble you before. |
Hoarseness | A sudden, unexplained change in voice, often indicating nerve involvement. |
Recurrent Infections | Repeated bronchitis or pneumonia in the same lung area. |
Systemic Signs | Unexplained weight loss, loss of appetite, fatigue, or bone pain. |
If you are over 40 with a history of smoking, secondhand smoke exposure, occupational dust/chemical exposure, or family history of lung cancer, annual low-dose CT screening can detect tumors when they are still tiny and curable.
At Fosun Health, diagnosis is not just about "finding cancer"—it is about mapping every detail of your tumor to design the most precise battle plan. Our streamlined diagnostic pathway delivers answers within days, not weeks:
A quick, painless scan that detects nodules as small as a few millimeters—far before symptoms appear.
We use the least invasive method possible to obtain a definitive diagnosis:
- EBUS-TBNA (Endobronchial Ultrasound): A tiny ultrasound probe navigates your airways to sample lymph nodes with no external incision.
- CT-Guided Core Biopsy: A thin needle precisely targets peripheral lung lesions under real-time imaging.
- Liquid Biopsy: A simple blood draw detects circulating tumor DNA when tissue sampling is difficult.
- PET-CT: Reveals the tumor's metabolic activity and detects hidden spread to lymph nodes, bones, or organs.
- Brain MRI & Bone Scan: Rules out common metastatic sites to ensure accurate stage classification.
Using NGS (Next-Generation Sequencing), we analyze over 300 cancer-related genes to identify driver mutations (EGFR, ALK, ROS1, MET, KRAS, etc.) and predict your response to targeted therapy or immunotherapy. This ensures your treatment is matched to your tumor's unique biology—not a one-size-fits-all protocol.
Every lung cancer program has surgery, drugs, and radiation. Here is what makes ours different—and why patients from across the region choose Fosun Health:
"The tumor moves with every breath. How do you hit it without destroying my healthy lung?"
The challenge: Lung tumors shift up to 2 cm with each breath. Conventional radiation enlarges safety margins, damaging healthy tissue. Patients told they are "not surgical candidates" often face a treatment gap.
Our answer: CyberKnife M6 with real-time respiratory tracking and 6D robotic positioning. The system sees your tumor move and synchronizes beam delivery from 1,600+ angles. 0.1mm precision. No enlarged margins. No damage to healthy lung, heart, or spinal cord.
With 25+ years of continuous lung-tracking evolution, our team has treated thousands of thoracic cases:
- Early-stage or oligometastatic tumors: 1–5 non-invasive sessions, curative intent. No anesthesia. No incisions.
- Medically inoperable patients: A genuine curative alternative, not just palliation.
- Tumors near the heart, bronchi, or spine: Treated safely because the beam follows the tumor.
What this means for you: If your body cannot tolerate a scalpel, CyberKnife offers a non-invasive, anesthesia-free, precision-ablative cure—while your healthy lung keeps breathing normally.
"I cannot have surgery—or the tumor is too advanced. Is this the end?"
The challenge: Many patients are not surgical candidates. Systemic drugs alone rarely achieve the local control needed to open a curative window. And some tumors sit in limbo—too advanced for immediate surgery, but not beyond hope if they could only shrink.
Our answer: A dual-track interventional platform—needle-based and catheter-based. No open chest. No general anesthesia for the procedure.
Track One: Physical destruction
When surgery is not the best path, we eliminate the tumor physically:
- Thermal & cryoablation: RFA, MWA, or cryoablation via a single needle puncture under CT guidance. Burn it, microwave it, or freeze it—millimeter precision, healthy tissue untouched. Cryoablation's natural pain-numbing effect makes it ideal for painful bone metastases.
- Iodine-125 seeds: Rice-grain-sized radioactive seeds implanted directly into metastatic lymph nodes or bone lesions. One procedure, 60–180 days of continuous internal radiation. No daily hospital visits.
- Tumor hyperthermia: Heating the tumor to 40–43°C disrupts DNA repair and sensitizes cancer cells to radiation and chemotherapy—a force multiplier that makes the same dose work harder, toxicity unchanged.
Track Two: Conversion therapy:
When the goal is to shrink the tumor toward surgery:
- Superselective transarterial infusion: Microcatheter-delivered chemotherapy directly into tumor-feeding arteries. Local drug concentration reaches 50–100× that of IV therapy, minimal systemic side effects.
- D-TACE: Blocks blood supply while releasing chemotherapy locally—"starving + poisoning" the cancer.
- Organ-directed prolonged infusion: Sustained high-dose regional therapy adapted for thoracic tumors.
After 1–3 sessions, tumors often shrink significantly—converting "unresectable" to "surgical candidate."
What this means for you: "Unresectable" is a snapshot, not a sentence. Whether your tumor needs to be ablated, seeded, heat-sensitized, or shrunk via targeted arteries—we give you physical lines of attack that drugs alone cannot provide. More options. More time. More paths to definitive control.
"If I need surgery, can you take only the cancer and leave the rest of my lung?"
The challenge: Conventional surgery too often removes more lung than the cancer demands—permanent loss of breathing capacity.
Our answer: Robotic-assisted anatomical segmentectomy and precision lobectomy. 10× magnified 3D vision, tremor-free wristed instruments. Sub-millimeter navigation through the bronchial tree and pulmonary vessels. Only diseased tissue is removed; every viable unit of healthy lung stays.
What this means for you: Cancer out. Healthy lung stays. Radical does not have to mean excessive.
"When my first targeted drug stops working, what comes next—and when?"
The challenge: Resistance is inevitable. In many regions, patients wait years for the next approved agent—if it ever arrives.
Our answer: In China, the next line comes sooner. Asian-prevalent mutations (EGFR, ALK, ROS1, MET exon 14 skipping, RET fusions) have driven East Asian-pioneered strategies. Fourth-generation EGFR-TKIs, novel ALK inhibitors, bispecific antibodies, and China-original combinations are in routine use here—often while still in trials elsewhere.
Guided by physicians who have managed thousands of cases with these exact drugs.
Clinical Trial Fast-Track
When standard therapies reach their limit, we provide rapid access to China's full portfolio of Phase III clinical trials—therapies typically 3–5 years ahead of availability elsewhere. NGS-based molecular matching identifies trials targeting your specific mutation. Every enrollment is ethics-approved with full medical supervision.
Integrative Oncology & TCM
Our TCM program runs parallel to your primary treatment with two goals: toxicity reduction(protecting organ function, easing nausea and fatigue, reducing myelosuppression) and efficacy enhancement (selected preparations may improve tumor sensitivity to treatment). Acupuncture provides additional support for pain, nausea, and fatigue.
Every lung cancer case at Fosun Health is reviewed by a panel comprising thoracic surgery, medical oncology, radiation oncology, interventional radiology, radiology, and pathology specialists. The MDT convenes within 48 hours of complete documentation to deliver a unified, individualized plan—ensuring that when surgery, radiosurgery, targeted therapy, or immunotherapy are all valid options, the choice is driven by collective expertise rather than departmental bias.
A 65-year-old male patient was diagnosed with esophageal cancer that had metastasized to the lungs. Due to his underlying health conditions, he declined surgical treatment.
After a thorough evaluation, Director Lu recommended CyberKnife stereotactic body radiotherapy (SBRT) as an alternative. The patient underwent one treatment course, receiving 11 Gy per session for a total of five sessions (11 Gy × 5 fractions).
- Prescription dose: 11 Gy × 5F
- Prescription isodose line: 63%
Radiation Therapy Plan:
Patient's Cyberknife Radiotherapy Plan
After just five treatment sessions, the patient showed significant clinical improvement. A follow-up one month after radiotherapy revealed that the original lung lesions had completely disappeared.
Before & After Radiotherapy Treatment
Mr. Li (pseudonym), a 71-year-old man, underwent a chest CT scan due to a persistent cough and was diagnosed with a right lung tumor. PET-CT further revealed central-type lung cancer in the right upper lobe, with bilateral hilar and mediastinal metastases. Pathological examination confirmed non–small cell lung cancer (NSCLC).
Doctor having a discussion with the patient
After carefully weighing the options, Mr. Li decided to proceed with the CyberKnife treatment plan. The CyberKnife treatment went smoothly, and Mr. Li experienced minimal side effects. Shortly afterward, he developed a temporary worsening of his cough, which quickly resolved with a combination of steroid and antibiotic therapy. After returning home, he continued targeted therapy for about one month, but due to severe side effects, he discontinued it and switched to traditional Chinese medicine for ongoing care.
2019 CyberKnife Treatment Plan
Both the right lung tumor and metastatic lymph nodes were treated with CyberKnife — initially with five large irradiation beams, followed by four smaller, focused beams. After treatment, Mr. Li experienced only mild coughing.
June 2021 Follow-up:
A follow-up PET-CT scan revealed that the irregular nodule near the right upper hilum had become blurred, surrounded by dense, fibrotic streaks clearly visible on imaging, with extremely low metabolic activity. These findings indicated that the tumor was completely necrotic — and the lymph node metastases had also disappeared entirely.
Patient: Female, 72 years old
Diagnosis: Non–Small Cell Lung Cancer (NSCLC)
The patient had a history of smoking and chronic obstructive pulmonary disease (COPD). She was initially diagnosed with a right upper lobe (RUL) lung lesion, which was PET-positive. Four years ago, the lesion measured 1 cm in diameter and showed no metabolic activity, so no intervention was performed at that time.
However, she later developed severe shortness of breath and coughing. A repeat chest CT revealed that the lesion had enlarged to 1.5 × 1.2 cm. A biopsy confirmed non–small cell lung cancer, and she was diagnosed with Stage IA NSCLC (T1N0M0).
CyberKnife Treatment Plan Parameters
- Tumor volume: 3.6 cm³
- Prescription dose: 54 Gy / 3 fractions
- Target coverage: 100%
- Tracking system: Xsight Lung Synchrony (no fiducial markers required)
- Algorithm: Monte Carlo algorithm
- Collimator size:*20–30 mm
- Number of beams: 148
- Prescription isodose line: 75%
Results and Follow-up
At 11 months post-treatment, PET-CT imaging showed no evidence of active disease, with only residual scarring visible. PET results were negative for metabolic activity. The patient remained in good overall condition, with no reported adverse complications following CyberKnife treatment.
Led by Dr. Yang Jun, Prof. Luo Pengfei, and Prof. Chen Tao, the Fosun Oncology Center brings together more than 20 world-class medical experts, each with over a decade of extensive oncology experience. Supported by a comprehensive range of advanced therapies — including robotic surgery, precision radiotherapy, minimally invasive intervention, CAR-T cell therapy, and Tumor Treating Fields (TTFields) — the center delivers one-stop, integrated cancer care designed to make treatment more accessible, efficient, and high-quality for every patient.
Key Highlights
- Over 60,000 annual oncology patient admissions across Fosun’s major international hospitals in 2025
More than 17,000 cumulative TACE procedures completed between 2023 and 2025 at Fosun Hospital Guangzhou alone, with international patients accounting for over 10% of total cases
- More than 1,000 successful CyberKnife treatments performed, demonstrating world-class expertise in precision radiotherapy
- A 29.3% five-year survival rate achieved for Glioblastoma Multiforme (GBM) through combined TTFields therapy, representing a significant improvement over the 4.7% baseline
Core Services
- Robotic surgery
- Precision radiotherapy
- Minimally invasive intervention
- CAR-T cell therapy
- Tumor Treating Fields (TTFields)
- Medical oncology
- PET/CT imaging
- Pulmonary nodule diagnosis
- VIP inpatient wards
- Integrated oncology clinics
- Traditional Chinese medicine for oncology
- Cancer screening and early detection
- Genetic testing and counseling
Fosun & Fosun Health
Founded in 1992, Fosun has grown over the past three decades into a global innovation-driven consumer group. In 2007, Fosun International Limited was listed on the Main Board of the Hong Kong Stock Exchange (stock code: 00656.HK). As one of the few Chinese enterprises with strong global operational and investment capabilities, Fosun has developed substantial technological expertise and innovation capacity across multiple industries.
Established in 2010, Shanghai Fosun Health Technology is dedicated to building a world-renowned healthcare group in Asia. Today, the group operates 19 affiliated medical institutions across Foshan, Guangzhou, Shenzhen, Zhuhai, Shanghai, and other major cities, with a total of 6,600 hospital beds and 9 Internet Hospital licenses. Fosun Health ranks No. 1 among China’s private comprehensive medical groups. Its flagship institution, Fosun Foshan Chancheng Hospital, has ranked first among private hospitals in China for eight consecutive years and was honored with the 2026 Global Health Asia-Pacific “Oncological Medical Service Provider of the Year” award.
As the flagship hospital of Fosun Health, Fosun Foshan Chancheng Hospital was founded in 1958. The hospital currently hosts 28 key specialty development programs, including 2 provincial-level, 13 municipal-level, and 13 district-level key specialties. Its services span 22 medical disciplines, including spinal orthopedics, traditional Chinese medicine gynecology, obstetrics and gynecology, cardiovascular medicine, clinical laboratory medicine, anesthesiology, pediatrics, critical care medicine, ultrasound medicine, rehabilitation medicine, general practice, general surgery, and urology.
The hospital is equipped with globally advanced medical technologies, including the CyberKnife system and the Da Vinci Surgical Robot. It has 1,750 approved hospital beds and a multidisciplinary team of more than 2,800 medical professionals. The hospital records nearly 3.19 million outpatient visits annually and more than 67,000 inpatient discharges each year.
Fosun Foshan Chancheng Hospital has received numerous prestigious recognitions, including:
Global Health Asia-Pacific “Traditional Chinese Medicine Hospital of the Year”
Global Health China “Hospital of the Year”
No. 1 ranking on the GAHA Top 500 Private Hospitals in China list for eight consecutive years
The hospital has also been recognized as:
A National Model Unit for Improved Medical Services
A National Drug Clinical Trial Institution (GCP)
A National Standardized Residency Training Base
Established in 2003, Guangzhou Fosun Chancheng Hospital specializes in cardiovascular medicine, oncology, and neurosciences. The hospital has established a National Chest Pain Center, Stroke Center, Trauma Center, and MDT Center, supporting the development of emergency medicine, obstetrics and gynecology, intensive care, anesthesiology, gastroenterology, general surgery, urology, and general practice.
The hospital operates more than 800 inpatient beds and 48 clinical and medical technology departments, supported by a team of over 880 healthcare professionals.
Guangzhou Fosun Chancheng Hospital has received several honors and industry recognitions, including:
EMBA Innovation Practice Base
Guangdong Private Medical Reform & Innovation Brand
Guangdong Private Medical Industry Pioneer Brand
Outstanding Brand Hospital for Medical Investment Contribution
Upload your medical documentation (CT/MRI images, PET-CT reports, pathology slides/reports, NGS/genetic sequencing results). The Fosun Health Lung Cancer MDT Panel will conduct a comprehensive evaluation and deliver a personalized preliminary treatment plan within 48 hours.
